S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NASDAQ:MNKD

MannKind - MNKD Stock Forecast, Price & News

$3.09
+0.10 (+3.34%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.00
$3.22
50-Day Range
$2.99
$4.35
52-Week Range
$2.49
$5.44
Volume
4.28 million shs
Average Volume
5.35 million shs
Market Capitalization
$780.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

MannKind MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.2% Upside
$6.00 Price Target
Short Interest
Bearish
13.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of MannKind in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$53,033 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.38) to ($0.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

720th out of 1,093 stocks

Pharmaceutical Preparations Industry

346th out of 547 stocks

MNKD stock logo

About MannKind (NASDAQ:MNKD) Stock

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

Interesting MNKD Call Options For October 28th
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
See More Headlines
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Company Calendar

Last Earnings
8/09/2022
Today
10/01/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
348
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+94.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-80,930,000.00
Net Margins
-133.37%
Pretax Margin
-133.37%

Debt

Sales & Book Value

Annual Sales
$75.44 million
Book Value
($0.83) per share

Miscellaneous

Free Float
246,756,000
Market Cap
$780.44 million
Optionable
Optionable
Beta
1.74

Social Links


Key Executives

  • Dr. Michael E. Castagna Pharm.D. (Age 45)
    CEO & Director
    Comp: $1.12M
  • Mr. Steven B. BinderMr. Steven B. Binder (Age 59)
    Chief Financial Officer
    Comp: $772.05k
  • Mr. Joseph Kocinsky M.B.A. (Age 58)
    M.S., Chief Technology Officer
    Comp: $608.75k
  • Dr. David B. ThomsonDr. David B. Thomson (Age 55)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $772.9k
  • Dr. Stuart A. Tross Ph.D. (Age 55)
    Chief People & Workplace Officer
    Comp: $652.85k
  • Mr. Thomas Hofmann M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Rosabel Realica Alinaya (Age 61)
    VP of Investor Relations & Treasury
  • Mr. John F. Bedard (Age 72)
    Sr. VP of Worldwide Regulatory Affairs
  • Mr. James Patrick McCauley Jr. (Age 56)
    J.D., M.B.A., Chief Commercial Officer
  • Mr. Alejandro  Galindo M.B.A.Mr. Alejandro Galindo M.B.A. (Age 50)
    M.S., Exec. VP of Endocrine Bus. Unit













MNKD Stock - Frequently Asked Questions

Should I buy or sell MannKind stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings
or view top-rated stocks.

What is MannKind's stock price forecast for 2022?

3 Wall Street analysts have issued twelve-month price objectives for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 94.2% from the stock's current price.
View analysts price targets for MNKD
or view top-rated stocks among Wall Street analysts.

How have MNKD shares performed in 2022?

MannKind's stock was trading at $4.37 on January 1st, 2022. Since then, MNKD shares have decreased by 29.3% and is now trading at $3.09.
View the best growth stocks for 2022 here
.

When is MannKind's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our MNKD earnings forecast
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analyst estimates of $15.62 million. The business's revenue was down 18.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $3.09.

How much money does MannKind make?

MannKind (NASDAQ:MNKD) has a market capitalization of $780.44 million and generates $75.44 million in revenue each year. The biopharmaceutical company earns $-80,930,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does MannKind have?

The company employs 348 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.